HIV treatment and prevention on every 2026 New York Part D plan
Pick a drug class, or type the drugs you want to check, and see which of the 10 stand-alone Part D plans in New York cover each one, on what tier, and with what restrictions.
- Covered
- Covered, needs prior authorization (PA) or step therapy (ST)
- Not on the formulary
- QL 60/30d = quantity limit, 60 units per 30 days
| Drug | HealthSpring Assurance Rx$35.70/moS5617-013 | Wellcare Value Script$42.40/moS4802-138 | Wellcare Classic$45.70/moS4802-077 | HealthSpring Extra Rx$91.60/moS5617-353 | AARP Medicare Rx Saver from UHC$105.80/moS5921-379 | SilverScript Choice$116.00/moS5601-006 | Humana Basic Rx Plan$140.90/moS5884-216 | Humana Value Rx Plan$158.90/moS5884-218 | AARP Medicare Rx Preferred from UHC$163.70/moS5921-382 | Humana Premier Rx Plan$173.60/moS5884-217 |
|---|---|---|---|---|---|---|---|---|---|---|
| Biktarvybictegravir/emtricitabine/tenofovir alafenamide | Tier 525% | Tier 525% | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 531%QL 30/30d | Tier 533%QL 30/30d |
| Dovatodolutegravir and lamivudine | Tier 525% | Tier 525% | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 531%QL 30/30d | Tier 533%QL 30/30d |
| Triumeqabacavir/dolutegravir/lamivudine | Tier 429%QL 300/30d | Tier 440% | Tier 428% | Tier 429%QL 300/30d | Tier 438%QL 180/30d | Tier 433% | Tier 430%QL 180/30d | Tier 431%QL 180/30d | Tier 428%QL 180/30d | Tier 450%QL 180/30d |
| Genvoyaelvitegravir/cobicistat/emtricitabine/tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 531%QL 30/30d | Tier 533%QL 30/30d |
| Odefseyemtricitabine/rilpivirine/tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 531%QL 30/30d | Tier 533%QL 30/30d |
| Symtuzadarunavir/cobicistat/emtricitabine/tenofovir alafenamide | Tier 525% | Tier 525% | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 531%QL 30/30d | Tier 533%QL 30/30d |
| Julucadolutegravir and rilpivirine | Tier 525% | Tier 525% | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 531%QL 30/30d | Tier 533%QL 30/30d |
| Descovyemtricitabine and tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 531%QL 30/30d | Tier 533%QL 30/30d |
| Truvadaemtricitabine and tenofovir disoproxil | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| emtricitabine-tenofovirgeneric Truvada | Tier 429%QL 30/30d | Tier 440%QL 30/30d | Tier 428%QL 30/30d | Tier 429%QL 30/30d | Tier 438%QL 30/30d | Tier 433%QL 30/30d | Tier 430%QL 30/30d | Tier 431%QL 30/30d | Tier 428%QL 30/30d | Tier 450%QL 30/30d |
| Tivicaydolutegravir | Tier 429%QL 180/30d | Tier 525% | Tier 525% | Tier 429%QL 180/30d | Tier 525%QL 60/30d | Tier 525% | Tier 525%QL 60/30d | Tier 526%QL 60/30d | Tier 531%QL 60/30d | Tier 533%QL 60/30d |
Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.